Session » SLE – Treatment Poster II

Date: Sunday, November 13, 2022

Time: 9:00AM-10:30AM

Meeting: ACR Convergence 2022

9:00AM-10:30AM: Abstract Number: 0987

A Randomized Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Systemic Lupus Erythematosus and Other Autoantibody-Associated Diseases

9:00AM-10:30AM: Abstract Number: 0998

A Real-world Analysis Showing Significant Variance in Treatment Patterns Among over 1,000 Systemic Lupus Erythematosus (SLE) Patients in the US

9:00AM-10:30AM: Abstract Number: 0995

Association of Glucocorticoid Use with Healthcare Utilization Among Persons with Systemic Lupus Erythematosus

9:00AM-10:30AM: Abstract Number: 0978

Belimumab After Rituximab Targets IgA2 Anti-dsDNA Antibody Production and Shifts Repopulating B-cells Towards an Anergic, Non-pathogenic Phenotype in Systemic Lupus Erythematosus

9:00AM-10:30AM: Abstract Number: 0979

Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus: A Pooled Post Hoc Analysis of Five Phase 3, Randomized, Placebo-Controlled Clinical Trials

9:00AM-10:30AM: Abstract Number: 1000

Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis from the Phase 2 PAISLEY Study

9:00AM-10:30AM: Abstract Number: 0999

Differences in Chromatin Accessibility Pre- and Post-Induction Therapy in Pediatric Lupus

9:00AM-10:30AM: Abstract Number: 1003

Does LLDAS Definition Match the Rheumatologist Opinion? The First Visit Evaluation of a Longinudital Spanish Multicenter Study to Assess Reasons of Disagreement

9:00AM-10:30AM: Abstract Number: 1001

Effect of Atacicept on Renal Function in Patients with Systemic Lupus Erythematosus (SLE)

9:00AM-10:30AM: Abstract Number: 0977

Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE)

9:00AM-10:30AM: Abstract Number: 0982

Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression and Cardiovascular Events in Patients with Systemic Lupus Erythematosus

9:00AM-10:30AM: Abstract Number: 0994

Effect of Immunosuppression on COVID Vaccination in Systemic Lupus Erythematosus

9:00AM-10:30AM: Abstract Number: 0983

Hydroxychloroquine Use and Heart Failure with Preserved Ejection Fraction in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 0984

Impact of Hydroxychloroquine on Interferon Pathway Expression of SLE Phenotypic Subsets in the Absence of Background Medications

9:00AM-10:30AM: Abstract Number: 0986

Impact of Weight and Race on Renal Response to Cyclophosphamide in the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study (ACCESS)

9:00AM-10:30AM: Abstract Number: 0992

Interim Results from the Phase 2 MISSION Study Evaluating Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor for the Treatment of Lupus Nephritis

9:00AM-10:30AM: Abstract Number: 1002

Investigation of Pharmacodynamic Biomarkers in a Phase 2b Study in Patients with Moderate to Severe SLE Treated with the S1P1 Receptor Modulator Cenerimod

9:00AM-10:30AM: Abstract Number: 0990

KPG-818, a Novel Cereblon (CRBN) Modulator, in Patients with SLE: Results of a Phase Ib Multiple Ascending Dose Study

9:00AM-10:30AM: Abstract Number: 0976

Low-dose Belimumab and Antimalarial Agents Prevent Renal Flares in Systemic Lupus Erythematosus: Results from Four Randomised Clinical Trials

9:00AM-10:30AM: Abstract Number: 0975

Modulation of T, B, and Innate Cell-Associated Pharmacodynamic Biomarkers in a Phase 3 Trial of Anifrolumab in Moderate to Severe SLE

9:00AM-10:30AM: Abstract Number: 0991

Prior Use of Autoimmune Disease Treatments Among Patients with Systemic Lupus Erythematosus, Rheumatoid Arthritis, or Myositis Hospitalized with COVID-19

9:00AM-10:30AM: Abstract Number: 0981

QTc Prolongation in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients Treated with Hydroxychloroquine – Preliminary Results from a Single Center Study

9:00AM-10:30AM: Abstract Number: 0974

Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers

9:00AM-10:30AM: Abstract Number: 0989

Regulatory T Cell Defects in SLE and Therapy with a Novel IL-2 Mutein: Phase 1 Clinical Results with Efavaleukin Alfa

9:00AM-10:30AM: Abstract Number: 0985

S100 Serum Protein Expression Is a Useful Indicator of HCQ Treatment Efficacy in SLE

9:00AM-10:30AM: Abstract Number: 0988

Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Enpatoran Doses in a Phase I Study of Healthy Japanese and Caucasian Participants: Feasibility of Including Asian Participants in a Phase II Study of Enpatoran

9:00AM-10:30AM: Abstract Number: 0993

SARS-CoV-2 Vaccine Side Effects and Infections in SLE

9:00AM-10:30AM: Abstract Number: 0996

Tapering of Corticosteroids or Immunosuppressive Therapy in Stable SLE: A Comparison of Complete Remission, Clinical Remission and Lupus Low Disease Activity State in Protection Against Flares

9:00AM-10:30AM: Abstract Number: 0980

The Effect and Outcomes of HCQ Alone and in Combination with Anti-Depressants on QTc

9:00AM-10:30AM: Abstract Number: 0997

Withdrawal of Maintenance Glucocorticoid versus Other Immunosuppressants Among Patients with Systemic Lupus Erythematosus in Long Term Clinical Remission: Interim Analysis of a Non-inferiority Randomised Controlled Trial

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].